Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259518 | 1.00 | KYNU (0.60) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL2777678 | 1.00 | KYNU (0.60) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL31243031 | 0.92 | SIRT2 (0.62) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL677997 | 0.92 | FOLH1 (0.59) | FOLH1CTSKCTSLCTSSCTSB | |
| SCHEMBL2921260 | 0.92 | FOLH1 (0.59) | FOLH1CTSKCTSLCTSSCTSB | |
| SCHEMBL7624700 | 0.92 | FOLH1 (0.59) | FOLH1CTSKCTSLCTSSCTSB | |
| SCHEMBL7362144 | 0.91 | SIRT2 (0.67) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL5964588 | 0.90 | ALDH1A1 (0.60) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL7087075 | 0.90 | KYNU (0.59) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL11053442 | 0.90 | KYNU (0.59) | KYNUALDH1A1ALOX15SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | AMGEN INC. | 2025-09-18 | — | — | US | claimed |
| EP-4519278-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | Amgen Inc. (US) | 2025-03-12 | — | — | EP | claimed |
| CN-119562958-A | Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof | 安进公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-118108633-A | Preparation method of L-glufosinate intermediate (S) -2- (((benzyloxy) carbonyl) amino) but-3-enoic acid methyl ester | 浙江工业大学 | 2024-05-31 | — | — | CN | claimed |
| WO-2023215306-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | AMGEN INC. (US) | 2023-11-09 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-5876492-A | Ink compositions containing esters | XEROX CORPORATION (US) | 1999-03-02 | — | — | US | claimed |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2026-02-17 | — | — | US | disclosed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-02-17 | — | — | US | disclosed |
| US-4591459-A | Intermediates for 6-(aminoacyloxymethyl) penicillanic acid 1,1-dioxides | PFIZER INC. (US) | 1986-05-27 | — | — | US | disclosed |
| EP-0167204-A1 | Method for improving the absorption and effectiveness of a catecholamine compound | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1986-01-08 | — | — | EP | disclosed |
| US-4503040-A | 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1985-03-05 | — | — | US | disclosed |
| US-4452897-A | ENZYME HYDROLYSIS OF AMINOGLUTARIC ACID ALKYL ESTERS | TAKARA SHUZO CO., LTD. (JP) | 1984-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | NSUN3, NSUN2, SNRPA1 | KYNU 4309/4885ALDH1A1 3400/4885ALOX15 2788/4885 |
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | ENGASE, MAN2B2, GALNT2 | KYNU 3302/4885ALDH1A1 3478/4885ALOX15 4152/4885 |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | KYNU 2825/4885ALDH1A1 3087/4885ALOX15 4290/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | KYNU 2054/4885ALDH1A1 4675/4885ALOX15 4434/4885 |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | FCGR2A, FCGR3B, FCGR1A | KYNU 3594/4885ALDH1A1 4586/4885ALOX15 3756/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | KYNU 2825/4885ALDH1A1 3087/4885ALOX15 4290/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | KYNU 2825/4885ALDH1A1 3087/4885ALOX15 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.